Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.
A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who reported having “low” physical function, such as struggling to do strenuous work or take walks, derived significantly greater survival benefits from treatment with daratumumab (Darzalex Faspro, Johnson & Johnson/Janssen) than those who had “high” function.
“These findings are a reminder that good cancer care isn’t just about prescribing the right drug,”